TCR2 Therapeutics Inc. Common Stock, also called TCR2 Therapeutics, is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. Read More The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.